The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07356154

Phase 1

Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant

The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graf…

LeukemiaHigh Risk Acute Lymphoblastic LeukemiaHigh Risk Acute Myeloid Leukemia+11 more

~Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT06839456